Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 4
1(50.0%)
2Total
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03088111Phase 4Unknown

An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

Role: collaborator

NCT04170309Completed

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

Role: collaborator

NCT02547818Phase 3Completed

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

Role: collaborator

All 3 trials loaded